Dr. Robert M. Langdon
Claim this profileNebraska Methodist Hospital
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
13 reported clinical trials
42 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
Stage IV
Stage III
Stage II
2Lung Cancer
Stage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Robert M. Langdon is currently running
Osimertinib
for Non-Small Cell Lung Cancer
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Recruiting1 award Phase 242 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
More about Robert M. Langdon
Clinical Trial Related10 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Robert M. Langdon has experience with
- Carboplatin
- Pembrolizumab
- Biospecimen Collection
- Paclitaxel
- Osimertinib
- Pemetrexed
Breakdown of trials Robert M. Langdon has run
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Robert M. Langdon specialize in?
Robert M. Langdon focuses on Non-Small Cell Lung Cancer and Lung Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Robert M. Langdon currently recruiting for clinical trials?
Yes, Robert M. Langdon is currently recruiting for 5 clinical trials in Omaha Nebraska. If you're interested in participating, you should apply.
Are there any treatments that Robert M. Langdon has studied deeply?
Yes, Robert M. Langdon has studied treatments such as Carboplatin, Pembrolizumab, Biospecimen Collection.
What is the best way to schedule an appointment with Robert M. Langdon?
Apply for one of the trials that Robert M. Langdon is conducting.
What is the office address of Robert M. Langdon?
The office of Robert M. Langdon is located at: Nebraska Methodist Hospital, Omaha, Nebraska 68114 United States. This is the address for their practice at the Nebraska Methodist Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.